Quantcast

Latest gastrointestinal stromal tumor Stories

2009-05-15 09:34:27

Researchers at Fox Chase Cancer Center uncovered a genetic pattern that may help predict how gastrointestinal stromal tumor (GIST) patients respond to the targeted therapy imatinib mesylate (Gleevec). Moreover, their findings point to genes that could be suppressed in order to make these tumors respond more readily to imatinib.

2009-05-08 00:00:00

FRIMLEY, England, May 8 /PRNewswire/ -- - Glivec(R) (imatinib) Now Approved in the UK for Post-Surgery Treatment of Patients With KIT (CD117)-Positive Gastrointestinal Stromal Tumours (GIST), who are at Significant Risk of the Cancer Returning After Surgery(1) - Use of Glivec(R) After Surgery Significantly Reduces Risk of Cancer Relapse(2) - If Untreated After Surgery, 50% of patients Will Experience Their Cancer Returning Within Two Years(3,4) Glivec(R) has been approved...

2009-03-18 17:37:00

- Estimated one-year, recurrence-free survival was 98% for Kit-positive GIST patients taking Gleevec vs.

2009-01-15 06:34:50

New research published in the January issue of the Journal of the American College of Surgeons shows that laparoscopic removal of gastrointestinal stromal tumors (GISTs) is safe and effective, with a disease-free survival rate of nearly 80 percent after an average follow-up time of three and a-half years.

2008-12-19 18:41:00

Use of Gleevec after surgery shows significant benefit for gastrointestinal stromal tumor (GIST) patients, dramatically reducing risk of relapse GIST, a life-threatening cancer, recurs in as many as one of two patients; recurrent tumors are often more aggressive than primary tumors For GIST patients who were assigned to Gleevec, more than nine out of 10 remained cancer-free based on a 14-month median follow up EAST HANOVER, N.J., Dec.

2008-10-27 12:00:30

Infinity Pharmaceuticals, a cancer drug discovery and development company, has initiated a Phase III registration trial of IPI-504, its lead inhibitor of heat shock protein 90, in patients with refractory gastrointestinal stromal tumors.

2008-09-08 18:00:09

Pfizer announced today that important study results involving the company's leading anticancer agent, SUTENT(R) (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12--16 September 2008.

2008-07-02 09:00:13

Rationale: Platelet-derived growth factor (PDGF) promotes the proliferation and migration of pulmonary artery smooth muscle cells (PASMCs), and may play a role in the progression of pulmonary arterial hypertension (PAH), a condition characterized by proliferation of PASMCs resulting in the obstruction of small pulmonary arteries.

2008-06-05 03:00:07

By Edwards, Michael A Beatty, John S; Shah, Malay B; Bittner, James G IV To the Editor: Non-epithelial mesenchymal tumors, including gastrointestinal stromal tumors (GISTs) and smooth muscle tumors (SMTs), are rare and may occur in any part of the alimentary tract.1 GISTs originate from the interstitial cell of Cajal, an intestinal pacemaker cell, and represent 1 per cent to 3 per cent of all gastrointestinal malignant tumors.


Word of the Day
meacock
  • An uxorious, effeminate, or spiritless man.
  • A timorous, cowardly fellow.
Probably a blend of meek and cock, or from meek +‎ -ock (“diminutive suffix”).